The Royal Swedish Academy of Sciences (KVA) still needs time to assess whether the development of mRNA vaccines is worthy of a Nobel Prize, shared Secretary General Göran Hansson regarding their decision not to award this year’s Nobel Prize in either medicine or chemistry to the Hungarian biochemist.
This article was originally posted on our sister-site, Ungarn Heute. Translation by Júlia Tar.
As we already reported, surprisingly, Hungarian biochemist Katalin Karikó, who lives in the USA and has contributed significantly to the development of mRNA vaccines, did not receive this year’s Nobel Prize for medicine or for chemistry.
Karikó said to Hungarian Forbes regarding the award:
I only care about and focus on what I can change, what I can influence, and the prize committees are not one of those things.”
In scientific circles, many were surprised by the Swedish Academy’s decision, and the journal Science also questioned why the developers of the mRNA vaccines did not receive the Nobel Prize.
According to Tamás Freund, the president of the Hungarian Academy of Sciences (MTA), Karikó will have more chance for the prize after 1-2 years, because in the field of medicine it always takes some time for evaluation.
Göran Hansson, Secretary-General of the Royal Swedish Academy of Sciences, explained the decision as follows:
The development of mRNA vaccines is a wonderful success story that has had enormous positive consequences for humankind. And we’re all very grateful to the scientists. This is a kind of discovery that will receive nominations. But we need to take time.”
Featured image via Csilla Cseke/MTI